Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab vs Placebo as Adjuvant Therapy in HCC
NCT03859128Phase 3Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Toripalimab with Placebo (2 arms). Primary endpoint: Recurrence-Free Survival at 100 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03859128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859128.